Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Xenon Pharmaceuticals Inc.    XENE   CA98420N1050

XENON PHARMACEUTICALS INC.

(XENE)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/20/2020 11/23/2020 11/24/2020 11/25/2020 11/27/2020 Date
11.04(c) 10.97(c) 11.02(c) 11.34(c) 11.4(c) Last
166 997 170 227 125 238 69 417 107 602 Volume
+4.84% -0.63% +0.46% +2.90% +0.53% Change
More quotes
Financials (USD)
Sales 2020 30,4 M - -
Net income 2020 -29,8 M - -
Net cash position 2020 174 M - -
P/E ratio 2020 -13,2x
Yield 2020 -
Sales 2021 20,9 M - -
Net income 2021 -49,3 M - -
Net cash position 2021 318 M - -
P/E ratio 2021 -8,18x
Yield 2021 -
Capitalization 399 M 399 M -
EV / Sales 2020 7,42x
EV / Sales 2021 3,88x
Nbr of Employees 102
Free-Float 93,5%
More Financials
Company
Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD). Specifically, it is intended to treat LPLD in... 
More about the company
Notations Surperformance© of Xenon Pharmaceuticals Inc.
Trading Rating : Investor Rating :
More Ratings
All news about XENON PHARMACEUTICALS INC.
11/13Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences
GL
11/05Xenon Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provid..
GL
11/02Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Qu..
GL
10/08Xenon Pharmaceuticals Receives FDA Feedback and is on Track to Initiate XEN49..
GL
10/08Neurocrine Biosciences and Xenon Pharmaceuticals Provide Regulatory Update on..
GL
08/17Xenon Pharmaceuticals Appoints Dr. Chris Von Seggern as Chief Commercial Offi..
GL
08/06Xenon Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provi..
GL
08/04Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences
GL
07/30Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Q..
GL
05/21Xenon Pharmaceuticals Reports First Quarter 2020 Financial Results and Provid..
GL
05/14Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss First Qu..
GL
03/31Xenon Pharmaceuticals Provides Corporate Update in the Context of COVID-19
GL
03/26Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 563..
GL
03/09Xenon Pharmaceuticals Reports 2019 Financial Results and Provides Corporate U..
GL
03/02Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss 2019 Fin..
GL
More news
News in other languages on XENON PHARMACEUTICALS INC.
2018WALL STREET STOCK EXCHANGE : Les valeurs à suivre à Wall Street
More news
Chart XENON PHARMACEUTICALS INC.
Duration : Period :
Xenon Pharmaceuticals Inc. Technical Analysis Chart | XENE | CA98420N1050 | MarketScreener
Technical analysis trends XENON PHARMACEUTICALS INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Average target price 23,00 $
Last Close Price 11,40 $
Spread / Highest target 119%
Spread / Average Target 102%
Spread / Lowest Target 93,0%
EPS Revisions
Managers
NameTitle
Simon Neil Pimstone Chief Executive Officer & Director
Ian C. Mortimer President, Chief Financial Officer & Secretary
Michael M. Tarnow Chairman
Ernesto Aycardi Chief Medical Officer
Michael R. Hayden Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
XENON PHARMACEUTICALS INC.-13.04%399
WUXI APPTEC CO., LTD.56.53%37 916
BEIGENE, LTD.72.47%26 060
NEUROCRINE BIOSCIENCES, INC.-11.51%8 928
SPRINGWORKS THERAPEUTICS, INC.76.67%3 259
AXSOME THERAPEUTICS, INC.-27.26%2 808